Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer

We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness‐associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ER(pos)/HER2 (neg)), 1953...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivapiragasam, Abirami, Ashok Kumar, Prashanth, Sokol, Ethan S., Albacker, Lee A., Killian, Jonathan K., Ramkissoon, Shakti H., Huang, Richard S. P., Severson, Eric A., Brown, Charlotte A., Danziger, Natalie, McGregor, Kimberly, Ross, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826457/
https://www.ncbi.nlm.nih.gov/pubmed/33314633
http://dx.doi.org/10.1002/cam4.3550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826457/
https://www.ncbi.nlm.nih.gov/pubmed/33314633
http://dx.doi.org/10.1002/cam4.3550

Ejemplares similares